0.133

2.23% +0.0029

Zomedica Corp (ZOM)

Overview News Price History Discussions Forecast

Zomedica Corp stock is currently priced at $0.133, with a 24-hour trading volume of 2.54M. It has seen a +2.23% increased in the last 24 hours and a -4.93% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.1301 pivot point. If it approaches the $0.1334 resistance level, significant changes may occur.

Previous Close:

$0.1301

Open:

$0.1319

24h Volume:

2.54M

Market Cap:

$130.33M

Revenue:

$25.19M

Net Income/Loss:

$-34.53M

P/E Ratio:

-5.7826

EPS:

-0.023

Net Cash Flow:

$-20.62M

1W Performance:

+7.52%

1M Performance:

-4.93%

6M Performance:

-17.39%

1Y Performance:

-34.48%

1D Range:

$0.1319

$0.1343

52W Range:

$0.12

$0.245

Zomedica Corp Stock (ZOM) Company Profile

Name

Zomedica Corp

Sector

Healthcare (1191)

Industry

Drug Manufacturers - Specialty & Generic (4)

Phone

734-369-2555

Address

100 Phoenix Drive, Suite 190, Ann Arbor, MI

Employee

Twitter

@zomedica

Next Earnings Date

2024-05-09

Latest SEC Filings

ZOM's Discussions on Twitter

Zomedica Corp Stock (ZOM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-06-23	Initiated	Dawson James	Buy

Zomedica Corp Stock (ZOM) Financials Data

Zomedica Corp (ZOM) Revenue 2024

ZOM reported a revenue (TTM) of $25.19 million for the quarter ending December 31, 2023, a +33.05% rise year-over-year.

Zomedica Corp (ZOM) Net Income 2024

ZOM net income (TTM) was -$34.53 million for the quarter ending December 31, 2023, a -102.96% decrease year-over-year.

Zomedica Corp (ZOM) Cash Flow 2024

ZOM recorded a free cash flow (TTM) of -$20.62 million for the quarter ending December 31, 2023, a -62.42% decrease year-over-year.

Zomedica Corp (ZOM) Earnings per Share 2024

ZOM earnings per share (TTM) was -$0.036 for the quarter ending December 31, 2023, a -111.76% decline year-over-year.

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.